Technology Opportunity Webinar: Nestorone®/Testosterone Male Contraceptive Gel
December 12, 2023 | 11:00 AM – 12:00 PM
Webinar overview
Thank you for attending this free webinar. You would like to request a link to the recording, or you are interested in the learning more about the technology, please reach out to Joseph.Conrad@nih.gov.
**********
Attendees will learn about a first-of-its-kind male contraceptive hormonal gel, Nestorone®/Testosterone (NES/T), co-developed by the NICHD and Population Council through the Contraceptive Clinical Trials Network (CCTN). This topical daily self-applied transdermal gel is designed to provide full sperm suppression within 8-12 weeks and be reversible after 12-16 weeks of ending application. This presentation will showcase NES/T gel as an innovative user-controlled option for male contraception.
Presenters
Diana Blithe, Ph.D.
Program Chief
Contraceptive Development Program
Eunice Kennedy Shriver National Institute of Child Health & Human Development
Regine Sitruk-Ware, M.D.
Distinguished Scientist
Reproductive Endocrinologist
Population Council Center for Biomedical Research
About the Featured Technology
This novel technology was developed through a partnership of the NICHD and the Population Council, operating through the CCTN, that is dedicated to the co-development of male contraceptives. A partner is being actively sought to license and advance this product, currently in Phase IIb evaluation with interim data available, through the final stage of clinical testing, regulatory approval, and commercial launch. This novel NES/T male gel is the first hormonal male contraceptive product targeted to reach the market.
Population Council Center for Biomedical Research
Competitive Advantages
- Addresses a significant, unmet medical need given few current options for male contraceptives
- High observed efficacy
- Low rate of observed side effects
- Reversible (return to fertility)
- High level of acceptability
- Based on FDA approved compound (Nestorone® aka segesterone acetate) combined with transdermal testosterone (FDA approved) in a novel formulation
- Patent pending
Why attend?
- Learn more about the technology and opportunity for US/Global licensing
- Interact with the inventors, ask questions and provide feedback
Who should attend?
- Business development professionals
- Investors and entrepreneurs
- Scientific and drug development professionals
- Biotech/pharma/academia researchers